Enarodustat hydrochloride  (Synonyms: JTZ-951 hydrochloride; SAL0951 hydrochloride)

Enarodustat hydrochloride is a potent and orally active HIF/HIF Prolyl-Hydroxylase inhibitor, with an EC₅₀ of 0.22 μM. Enarodustat hydrochloride has the potential for renal anemia treatment.

pKi : 8.2 (5-HT_2A receptor), 8.0 (D₄ receptor), 6.7 (D₂ receptor), 7.2 (α₁ receptor), 6.9 (5-HT_2C receptor), 5.7 (H₁ receptor)^[1]

Enarodustat hydrochloride (JTZ-951) is a potent and orally active hypoxia-inducible factor prolyl hydroxylase inhibitor, with an EC₅₀ of 0.22 μM. Enarodustat hydrochloride exhibits neither CYP (IC₅₀ > 100 μM; CYP3A4/5, CYP2C9, CYP2D6, CYP1A2, CYP2A6, CYP2C19, CYP2C8, CYP2B6) nor hERG (IC₅₀ > 100 μM) inhibition^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Enarodustat hydrochloride (1 and 3 mg/kg, p.o.) increases hemoglobin levels in a dose-dependent manner with daily oral dosing in rats^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

376.79

C₁₇H₁₇ClN₄O₄

1262131-60-1

O=C(C(C1=NC=NN1C(CCC2=CC=CC=C2)=C3)=C3O)NCC(O)=O.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ogoshi Y, et al. Discovery of JTZ-951: A HIF Prolyl Hydroxylase Inhibitor for the Treatment of Renal Anemia. ACS Med Chem Lett. 2017 Nov 20;8(12):1320-1325.  [Content Brief]